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Abstract: 
 
The genomes of both bacteria and eukaryotic organisms are known to encode selenoproteins, 
using the UGA codon for selenocysteine (SeC), and a complex cotranslational mechanism for 
SeC incorporation into polypeptide chains, involving RNA stem-loop structures. These common 
features and similar codon usage strongly suggest that this is an ancient evolutionary 
development. However, the possibility that some viruses might also encode selenoproteins 
remained unexplored until recently. Based on an analysis of the genomic structure of the human 
immunodeficiency virus HIV-1, we demonstrated that several regions overlapping known HIV 
genes have the potential to encode selenoproteins (Taylor et al.[31], J. Med. Chem. 37, 2637–
2654 [1994]). This is provocative in the light of over-whelming evidence of a role for oxidative 
stress in AIDS pathogenesis, and the fact that a number of viral diseases have been linked to 
selenium (Se) deficiency, either in humans or by in vitro and animal studies. These include HIV-
AIDS, hepatitis B linked to liver disease and cancer, Coxsackie virus B3, Keshan disease, and 
the mouse mammary tumor virus (MMTV), against which Se is a potent chemoprotective agent. 
There are also established biochemical mechanisms whereby extreme Se deficiency can induce a 
proclotting or hemorrhagic effect, suggesting that hemorrhagic fever viruses should also be 
examined for potential virally encoded selenoproteins. In addition to the RNA stem-loop 
structures required for SeC insertion at UGA codons, genomic structural features that may be 
required for selenoprotein synthesis can also include ribosomal frameshift sites and RNA 
pseudoknots if the potential selenoprotein module overlaps with another gene, which may prove 
to be the rule rather than the exception in viruses. One such pseudoknot that we predicted in 
HIV-1 has now been verified experimentally; a similar structure can be demonstrated in 
precisely the same location in the reverse transcriptase coding region of hepatitis B virus. 
Significant new findings reported here include the existence of highly distinctive glutathione 
peroxidase (GSH-Px)-related sequences in Coxsackie B viruses, new theoretical data related to a 
previously proposed potential selenoprotein gene overlapping the HIV protease coding region, 
and further evidence in support of a novel frameshift site in the HIV nef gene associated with a 
well-conserved UGA codon in the-1 reading frame. 
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Article: 
 
INTRODUCTION 
 
An extensive body of evidence, documented in the current symposium proceedings, 
demonstrates that selenium (Se) deficiency has been linked to the incidence, disease progression, 
or virulence associated with a number of viral infections, either in humans or by in vitro and 
animal studies. Furthermore, Se has been shown to have significant chemoprotective effects 
against a number of human and animal viruses, including hepatitis B infection linked to liver 
disease and cancer (1,2), Coxsackie virus, Keshan disease (3,4), viral hemorrhagic fever (5), and 
the mouse mammary tumor virus (MMTV) (6). In the case of the acquired immune deficiency 
syndrome (AIDS) associated with infection by the human immunodeficiency virus (HIV), 
abnormalities in Se and other antioxidants have been consistently reported over the last decade 
(7-25). Furthermore, there is now extensive evidence of a role for oxidative stress in the 
pathogenesis of the viral infection (20,23). In the light of the chemoprotective effects of Se in the 
other viral diseases noted above, and the fact that Se has now been proven to be a potent 
inhibitor of HIV activation in vitro (26), definitive large-scale controlled studies of the potential 
benefits of Se supplementation in HIV+ populations are now strongly justified. 
 
It is possible that the explanation for this inverse correlation between host Se/antioxidant levels 
and viral pathogenesis lies almost entirely within the realm of known biochemistry, i.e., that it 
can be largely explained in terms of our current understanding of the importance of antioxidants 
for proper immune cell functioning, the role of oxidant tone in regulating gene expression, and 
the demonstrated ability of oxidative stress to activate viral replication. Antioxidant deficiencies 
can undoubtedly weaken host defenses, creating a more permissive environment for viral 
replication, yielding a larger pool of mutant viruses, which in turn can favor the emergence of 
more successful and potentially more virulent viral strains (27). However, the cogency and 
appeal of such explanations of this Se/antioxidant effect should not inhibit us from considering 
another possible contributing factor in the virus-host-antioxidant equation: the possibility that 
some viruses may perturb (or mimic) host antioxidant defenses by directly incorporating Se into 
viral proteins. 
 
In addition to the nonspecific substitution of selenomethionine for methionine that can 
potentially occur in all proteins when Se is bioavailable, the genomes of both prokaryotic and 
eukaryotic organisms are known to encode specific selenocysteine (SeC)-containing 
"selenoproteins." Both bacteria and eukaryotes use the UGA codon for SeC, and both utilize a 
complex cotranslational mechanism for SeC incorporation into polypeptide chains, involving 
RNA stem-loop structures (28,29). These common features and, most importantly, the similar 
codon usage, strongly suggest that the molecular biology of SeC incorporation into proteins 
("selenobiology') must predate the divergence between bacteria and higher organisms, and is thus 
an ancient evolutionary development. Bock and coworkers have elaborated on this possibility 
(28), and proposed that on the early earth of several billion years ago (when atmospheric oxygen 
levels were still very low), selenobiology may have been more prevalent than it is today, and 
hence that the UGA codon may have originally served primarily as a sense codon for SeC. Under 
this scenario, UGA may have evolved into its current predominant function as a signal for the 
termination of protein chains (a "stop codon") primarily by default, owing to the progressive 
decrease in the bioavailability of SeC in more recent evolutionary times, associated with the 
emergence of more oxidative conditions in the biosphere. 
 
Although this concept of primordial selenobiology is only a theory, it has significant implications 
when combined with another interesting hypothesis about RNA viruses and retroviruses, viz., the 
idea that some of the features or molecular machinery of such viruses may be relics or 
"molecular fossils" of the ancient RNA or (RNP) ribonucleoprotein world (30). In fact, it is now 
widely accepted that RNA-based life forms predominated early in evolution, prior to the switch 
to DNA as the primary repository of genetic information, a change that clearly must have 
required reverse transcriptase, the defining enzyme of retroviruses. 
 
As discussed previously (31), if there is any merit to these two theories, then by combining them, 
one should expect at least that RNA viruses in particular might contain vestigial features 
consistent with an ancient selenoprotein coding potential, or in some cases, that selenobiology 
might still be utilized by certain viruses as a modern adaptation of an ancient biochemical 
strategy. Distinguishing between such a vestigial feature and an active gene might be quite 
difficult in some cases, for reasons given at the end of the next section. 
 
Probably because of the very low abundance of Se, and the small number of selenoproteins so far 
identified (leading to the possibly incorrect impression that they are extremely rare), this 
possibility apparently remained unconsidered and unexplored until our proposal in 1994 of what 
in retrospect might be called the "viral selenoprotein theory," which arose initially from an 
analysis of the genomic structure of HIV-1 (31). We showed that several regions of the virus 
have the potential to encode selenoproteins, and that certain UGA codons in overlapping reading 
frames are well conserved in the many HIV-1 isolates that have been sequenced (31,32). 
Obviously, if HIV could make such proteins, there would have to be a reassessment of the 
mechanisms by which oxidative stress contributes to AIDS pathogenesis. 
 
In this article, we will assess the current status and scope of the viral selenoprotein theory in light 
of the rather extensive body of data on the interrelationships between various viral diseases and 
dietary Se/antioxidant status, much of which is described in detail in the other articles from this 
symposium. However, before presenting data on specific viruses, such as Coxsackie B (CBV) 
and HIV-1, we will make some general comments in regard to the protein coding potential of 
viruses and attempt a brief explanation of some of the structural features that are important for 
the genomic analyses that will be presented. 
 
THE POTENTIAL COMPLEXITY OF VIRAL GENOMES 
 
Although a nonspecialist might think it remarkable that a new gene could be discovered or 
proposed in a virus that has been characterized at the sequence level for over a decade, that 
possibility is by no means improbable if one understands the basis for the potential complexity of 
viral (or indeed all) genomes. That basis is immediately evident if one considers: 
 
1. The potential benefits to the virus of increasing its protein coding potential; 
2. The triplet nature of the genetic code, which creates the potential for three overlapping 
reading frames--actually six if the complementary strand is also present in the cell as 
RNA; and 
3. The various processes by which the simple linear translation of an "open" genomic region 
can be diverted to permit the translation of an otherwise inaccessible region (as described 
below). 
 
Viruses in particular are under considerable evolutionary pressure to maximize the information 
content of their genomes, because they are very limited in regard to the size of the DNA or RNA 
that can be packaged in their virions. Thus, they have evolved mechanisms that enable them to 
maximize the amount of protein coding information within a length of oligonucleotide. For 
example, by placing overlapping genes in different reading frames of the same nucleotide 
sequence, they can easily increase their coding density. This and other complex possibilities for 
increasing protein coding potential are summarized in Fig. 1. 
 
 
Fig. 1. Schematic diagram of PPCRs in an imaginary RNA transcript, showing the three possible 
reading frames for translation, F1-F3. Vertical lines are the locations of stop codons in each 
frame. Two major ORFs are shown as ORF1 and ORF2. Owing to its partial overlap with ORF1, 
even if it did not have a start codon, ORF2 could be expressed by various alternative 
mechanisms, including: (1) ribosomal frameshifting from ORF1, (2) RNA editing, or (3) RNA 
splicing, either of which could bring the ORF2 region in-frame to ORF1 in a subset of modified 
mRNAs. In all three cases, the protein product would be a fusion protein with its N-terminal 
derived from part of ORF1 and its C-terminal derived from part of ORF2. ORFI' could be 
expressed by suppression of the stop codon at the end of ORF1 (dashed vertical line), which 
would produce an extended form of the ORF1 protein. This analysis shows that there are various 
additional PPCRs in such a sequence, e.g., that indicated by the question mark, which, despite 
the lack of a start codon, could have potential to be expressed by alternative mechanisms if 
appropriate RNA editing, splicing, or frameshifting signals are present. Because specific 
structural features are involved in such events (e.g., heptameric or other frameshift sequences, 
RNA pseudoknots, splice acceptor and donor sequences, and so on), a detailed genomic analysis 
can sometimes reveal which PPCRs are the most likely to be functional, i.e., actually expressed 
as protein. 
 
There are at least three different ways in which noncontiguous potential coding regions can be 
brought together to permit the translation of a continuous protein chain: RNA splicing, RNA 
editing, and frameshifting. Viruses that are transcribed in the nucleus, like retroviruses, can 
exploit RNA splicing, a characteristic feature of eukaryotic organisms. Alternative RNA splicing 
can be used to coordinate the expression of different genes at certain stages of infection, as seen 
in complex retroviruses; it can also potentially be exploited to permit the modular construction of 
different proteins containing a common module, thus avoiding the needless duplication of 
precious genetic material. Ribosomal frameshifting can potentially be used to achieve the same 
sort of modular construction, by placing alternate 3' "exons" in two overlapping reading frames 
of the same oligonucleotide; when expressed, each is attached to a common module encoded in 
the 5'-region of the zero reading frame. A third way of attaining the same goal is RNA editing, 
where an alternate transcript is made with one or more ribonucleotides physically inserted or 
deleted (usually via slippage of the polymerase on a repetitive sequence), leading to a subset of 
transcripts in which otherwise out-of-frame regions are brought in-frame. This mechanism 
enables the Ebola virus to make two different forms of its glycoprotein gene product (33). 
 
Another possibility is that of potential protein coding regions that are in the same frame, but 
separated by a single stop codon. Some viruses suppress certain stop codons to enable a 
downstream module to be expressed, usually in low amounts relative to the upstream module, 
owing to the inefficiency of the readthrough mechanism (34). This process, commonly named 
after the type of stop codon being suppressed, as in "amber suppression," is also exploited by 
bacteria and eukaryotes. SeC insertion at UGA codons is conceptually a variant of this 
"termination suppression" mechanism, since UGA is normally a stop codon. 
 
Because of these multiple mechanisms by which various overlapping or downstream gene 
regions can be brought in-frame to an upstream region containing a start codon, we find the 
current terminology of "open" reading frame (ORF) vs "blocked" reading frame to be 
inadequate, since to call a region an ORF is to imply that it has a start codon at its 5'-end. We 
will use the more general term "potential protein coding region" (PPCR), which could apply to 
any gene region where there is at least a theoretical possibility that a protein segment could be 
translated by any of the mechanisms discussed above. 
 
Overlapping genes and processes like RNA splicing, editing, frameshifting, and suppression also 
present new opportunities for various forms of genetic regulation, beyond that attainable by 
transcriptional regulation alone. These processes potentially enable greater control over the 
expression of a greater variety of gene products than that attainable with a simple linear 
arrangement of nonoverlapping genes. 
 
Since in many cases the structural features required for such processes are by no means 
immediately evident, even on a detailed examination of a viral sequence, one must keep an open 
mind about the possibility of additional coding potential for new genes or gene variants in 
viruses. Furthermore, because a single virus can infect different cell types and even different host 
species at different stages of its life cycle, it is also possible that some "specialized" viral genes 
may be inactive in certain cell types or cell lines, or even within a particular host species, yet be 
expressed to play an active role in another host organism or cell type. Such considerations imply 
that in some cases, it may be quite difficult to prove or disprove experimentally or 
immunologically either the existence or the possible role of a particular hypothetical gene 
product identified in a viral genome. 
 
Nonetheless, one thing is very likely to be true: many viruses will prove to be more genetically 
complex than first expected. That has certainly proven to be the case with HIV and other 
"complex" retroviruses. 
 
FRAMESHIFTING REQUIRES "SHIFTY" SEQUENCES AND RNA SECONDARY 
STRUCTURES 
 
In retroviruses like HIV, the pol gene lacks a start codon, so the pol gene products can only be 
synthesized as gag-pol fusion proteins, most commonly by ribosomal frameshifting in the -1 
direction (35,36). The inefficiency of this process ensures the synthesis of only small amounts of 
the viral enzymes encoded in pol relative to the structural proteins encoded in gag, which are 
required in large quantities. Retroviral gag-pol -1 frameshift sites have been extensively studied, 
leading to the "simultaneous slippage" model developed by Varmus and coworkers (35). The 
frameshift involves the translocation of the RNA transcript by one base while two tRNA 
molecules are bound to the ribosome, and occurs on a specific nucleotide sequence in the mRNA 
that has a repetitive, "slippery" quality. For the most efficient frameshifting to occur (which is 
still only about 5% of the time), the slippery sequence ideally should be of the form X XXY 
YYZ, where triplets represent codons in the zero reading frame; however, deviations from this 
are known (37). It is also possible that a low-efficiency frameshift, and thus a less than ideal 
slippery sequence, could be desirable in some situations, e.g., where very low levels of a 
regulatory protein might be required. Mutagenesis studies have also shown that considerable 
deviation from this ideal pattern can still be associated with detectable levels of frameshifting 
(38). 
 
An RNA pseudoknot (PK) located 3' to the frameshift site (or in rare cases merely a stem-loop 
structure) is usually also required for efficient frameshifting to occur (39-41). The primary role 
of the PK in frameshifting may be merely to cause a pause in translation, but a more active role 
is also possible. 
 
It must also be noted that frameshifting with only one tRNA bound to the ribosomal P-site is 
known to occur in some cases, which would only require a 4-base shift signal in the message. 
This P-site slippage is often facilitated by a "hungry" codon in the second position (usually an 
Arg or Ser codon, but others are possible), which creates a pause owing to low cellular levels of 
the required isoacceptor tRNA, analogous to the pausing effect of RNA secondary structures, 
such as PKs (42). 
 
Frameshifting in the +1 direction is also well documented (39); a relevant example of a +1 
frameshift sequence is CCC followed by a stop codon, particularly CCCUGA (43), which will be 
discussed later in relation to its occurrence in the HIV-1 nef coding region. 
 
ALTERNATIVE FUNCTIONS OF THE UGA CODON AND SEC INSERTION 
MECHANISMS 
 
Even aside from its ability to encode selenocysteine, UGA is probably the most "leaky" of the 
three stop codons, any of which can be suppressed under appropriate circumstances, by means of 
mutant "suppressor" tRNAs and/or by programmed readthrough involving PKs, as seen in some 
retroviruses (34). When suppressed by such "conventional" mechanisms, UGA usually encodes 
an amino acid with a closely related codon, such as Trp, Cys, or Arg, in competition with 
termination, yielding a mixture of both the terminated product and an extended protein product. 
 
A unique role of the UGA codon is its potential to encode SeC. In eukaryotes, selenocysteine 
incorporation at UGA depends on the presence of a protein factor and a structural signal in the 
mRNA 3'-untranslated region, called an SeC insertion sequence or SECIS element (29,44,45). A 
possibly related stem-loop structure is required in bacteria, but must immediately follow the 
UGA codon (28). 
 
Finally, as mentioned above, if preceded by CCC or other shifty codons, an in-frame UGA can 
also be part of a frameshift signal, which may compete with termination and/or readthrough by 
any of the mechanisms listed above. 
 
CURRENT STATUS OF THE VIRAL SELENOPROTEIN THEORY 
 
At present, there has been no definitive demonstration that a potential selenoprotein gene is 
actually expressed by a virus. However, several specific predictions of the viral selenoprotein 
theory have now been verified. These include the following: 
 
1. One of the key RNA pseudoknots that we predicted in HIV-1, overlapping the codons at 
the active site of the reverse transcriptase gene and associated with a well-conserved 
UGA codon in the -1 reading frame, has now been validated experimentally by chemical 
and enzymatic cleavage studies, reported in a recent paper and thesis from Barbara 
Carter's group at the University of Toledo (46). 
2. Our prediction that Se should have an antiviral effect vs HIV has been independently 
verified in vitro by several investigators; note that this was not a novel prediction, since 
Schrauzer had first made it more than 10 years previously (24). Recently, Favier and 
coworkers (26) have studied the effects of Se supplementation on HIV-1 replication 
induced by oxidative stress in cell culture; significantly, they were totally unaware of our 
work at that time and chose to investigate this question based on completely independent 
lines of evidence. Noting that existing data "implicate an HIV-1 mediated antioxidant 
imbalance as an important factor in the progressive depletion of CD4 § T cells in AIDS," 
they demonstrated that in ACH-2 cells, at concentrations of 25-50 μg/L as sodium 
selenite, Se supplementation inhibits viral cytotoxic effects and the reactivation of HIV-1 
by hydrogen peroxide, decreases activation of NF-r an important cellular transactivator of 
HIV-1, and protects against activation of HIV-1 by tumor necrosis factor. Similarly, 
preliminary results from the lab of Raymond Schinazi of Emory University, based on the 
screening of several organic and inorganic Se compounds in a standard assay for anti-
HIV activity, indicate that certain simple Se compounds are active against HIV-1 at 
micromolar concentrations, comparable to plasma Se levels in healthy humans (47). 
3. Most significantly, our proposal that some viruses may encode selenoproteins, which was 
received with skepticism a year or two ago, has now been substantiated by new findings 
from a group at NIH. Bernard Moss of NIAID recently reported the newly sequenced 
genome of the pox virus Molluscum contagiosum (48). This virus contained an open 
reading frame that is highly homologous to the known mammalian selenoprotein 
glutathione peroxidase (GSH-Px), with 80% sequence identity at the amino acid level, 
and an identically placed in-frame UGA codon. Given that GSH-Px is a fairly large 
protein, it is astronomically improbable that this match could occur by chance; this must 
be a real selenoprotein gene. This also shows that viruses can gain some evolutionary 
advantage by encoding such an antioxidant protein, as we suggested previously (31). In 
the light of this finding, serious consideration must be given to our theoretical genomic 
evidence that selenoproteins are potentially encoded by HIV and other viruses like 
Coxsackie virus (31,32). 
4. We now have firm experimental evidence from our own lab (49) demonstrating 
frameshift activity at a potential novel site in HIV, associated with a previously predicted 
potential selenoprotein gene overlapping the nef coding region, with a highly conserved -
1 frameshift signal and UGA codon in the -1 reading frame (32). The results suggest that 
a significant level of frameshifting (around 5%) is taking place in this region. However, 
given the possible alternative roles of UGA codons discussed above, further work must 
be done to determine whether SeC is actually encoded by the conserved UGA codon in 
this novel variant of the HIV-1 nef protein. Theoretical data related to this potential gene 
will be presented below. 
 
POTENTIAL SELENOPROTEIN GENES IN HIV-1 AND COXSACKIE VIRUS: NEW 
THEORETICAL FINDINGS 
 
Since we have already published studies demonstrating the potential for several new genes in 
HIV-1 and Coxsackie virus (31,32), some of which may be selenoprotein genes, we will focus 
here only on new data related to several of the most important of these. We will also present new 
data showing highly distinctive GSH-Px-related sequences in CVB. 
 
A Potential GSH-Px Gene in Coxsackie Viruses 
 
We previously reported several potential selenoprotein genes in CVB (32), which have been 
implicated as a probable cofactor in Keshan disease, the classical Se-deficiency disease (3). Our 
findings thus suggest the possibility that viral selenoproteins may be an additional factor 
contributing to the observations of Beck et al., who have shown that the cardiovirulence of 
CVB3 is highly dependent on the Se status of the host, and that the virus actually mutates into a 
more virulent form in Se-deficient mice (4,27). 
 
Potential selenoprotein genes previously identified in CVB3 included a potential ORF encoded 
between bases 3442 and 3749, with a start codon and eight in-frame UGA codons, as well as 
eight Cys codons (32). The hypothetical protein has a strong sequence similarity to a whole 
family of proteins that contain epidermal growth factor (EGF) modules, which are commonly 
found in various extracellular matrix and cell-adhesion proteins (50). This match is also notable 
in that five out of the eight-UGA codons align precisely with Cys codons in the human EGF 
protein. Significantly, at least three other viruses are known to encode EGF homologs (51). 
 
A second potential selenoprotein in CVB3 may be encoded in a PPCR -1 to the main reading 
frame of CBV3, overlapping the entire vpg gene and much of the p3-c protease coding regions 
(32). This lacks a start codon, but could be expressed by a -1 frameshift owing to the presence of 
an "ideal" heptameric slippery sequence (GGGUUUU, beginning at position 5287) followed by a 
potential GC-rich PK located near the beginning of the vpg coding region of CBV3. The 
overlapping reading frame contains five in-frame UGA codons as well as five Cys codons. 
 
Whether these are functional genes in some Coxsackie virus strains, or merely artifacts or 
evolutionary relics remains to be determined. However, the former possibility seems more viable 
in the light of our discovery in CVB of a candidate GSH-Px gene--a known selenoprotein (Fig. 
2)--which, significantly is the same selenoprotein gene recently identified by Moss and 
coworkers in M. contagiosum (48). This potential GSH-Px gene in CVB was located by creating 
a data base of all known viral sequences, translating in all six reading frames, and using a 
mammalian GSH-Px-sequence as a data base probe for sequence similarities (see legend to Fig. 
2). The CVB4 sequence shown in the figure was a top hit in the search. Significantly, the region 
of strong sequence similarity found by the search corresponds precisely to the active site of the 
GSH-Px protein (Fig. 3). In CVB, this sequence overlaps a region of the main polyprotein 
reading frame that encodes vp3, one of the picornavirus structural (capsid) proteins. 
 
 
Fig. 2. Multiple sequence alignment of the catalytic core region of representative eukaryotic 
GSH-Px compared to GSH-Px-like sequences from Coxsackie virus strains B3 and B4. The 
asterisk indicates the position of the conserved catalytic selenocysteine (translated by the U 
symbol in the single-letter amino acid code). The viral sequences are shown in square braces; for 
easier comparison to the CVB4 sequence, one human GSH-Px-related sequence is placed below 
them, with matches to any of the three viral sequences highlighted in bold. Matches of amino 
acids in viral sequences to any in the aligned GSH-Px-sequences are indicated by underlining in 
the viral sequences. Numbers in brackets at the beginning of the viral sequences indicate the 
number of upstream residues to the preceding start codon (in CVB3) or stop codon (in CVB4). A 
potential frameshift around the glycine (G) codon following the CNQ sequence (see Fig. 4) 
would lead to a putative GSH-Px-vp3 fusion protein, shown here as CVB3-FUS. 
 
In the CVB4 strain with the highest local similarity to GSH-Px in the overlapping (+1) reading 
frame (Genbank #S76772), there is no start codon or apparent frameshift site, suggesting that the 
gene could not be active in that viral strain (unless some type of RNA editing or other unusual 
event is involved). However, in another CVB4 isolate (Genbank #D00149), the overlapping 
reading frame extends further upstream, and there is a start codon, as well as additional in-frame 
UGA codons. In CVB3 strains, there is also a start codon, and the entire catalytic site of GSH-Px 
is present within the span of 43 amino acids, suggesting that a highly truncated yet functional 
GSH-Px (Fig. 3) may be encoded in this potential ORF. It is also notable that, at least in CVB3 
strains, there is only a single UGA codon that aligns with the single UGA of GSH-Px that 
encodes the catalytic SeC. 
 
 
Fig. 3. X-ray crystal structure of GSH-Px-dimer with regions corresponding to the CVB3 GSH-
Px-like sequence shown in Fig. 2 highlighted in bold lines. Despite several internal deletions and 
truncation at the N- and C-terminals relative to the GSH-Px sequences, the 43-amino acid protein 
potentially encoded in the +1 frame of CVB3 includes the critical active site region of GSH-Px 
and sufficient supporting structure to function possibly as a highly truncated GSH-Px-like 
molecule. (Dot spheres show location of Se atoms.) 
 
 
Fig. 4. Potential -1 frameshift sites associated with GSH-Px-related sequences in CVB3 strains 
(left) and in some CVB4 strains (right). Schematic tRNAs are shown before (below) and after the 
shift (above) relative to the hypothetical slippery sequences (asterisks indicate cognate base 
pairings). Slippage here would involve a shift from the overlapping +1 frame into the vp3 coding 
region of CVB, giving a GSH-Px vp3 fusion protein. 
 
In both CVB3 and CVB4, it is also intriguing that downstream of this truncated GSH-Px coding 
region, sequence similarities to the C-terminal region of GSH-Px can still be observed in the 
main reading frame, i.e., within the vp3 protein sequence itself. In both the CVB3 and CVB4 
strains that have start codons in the GSH-Px-related ORF, there are potential -1 frameshift 
signals (Fig. 4) that could permit this GSH-Px module to be fused to the C-terminal half of vp3, 
in which certain residues might contribute to the GSH-Px activity, because they match conserved 
GSH-Px residues in the alignment (e.g., the EILN sequence at the far right of Fig. 2, just past the 
frameshift site). Such a hypothetical fusion protein sequence is shown in Fig. 2 as CVB3-FUS, 
which extends past the end of the CVB sequences in the +1 frame that terminate following the 
conserved GSH-Px active site sequences. 
 
If this frameshift site is active, out of the many copies of the vp3 protein synthesized, a small 
percentage (determined by frameshift efficiency and SeC availability) would contain a fused 
GSH-Px module. Because vp3 is a picornavirus structural protein present in about 60 
copies/virion, this implies that GSH-Px activity may be associated with the virion itself. This 
hypothesis can be tested using standard assays by harvesting virus from infected cells supplied 
with Se and assaying purified viral filtrates for GSH-Px activity. 
 
Independent of that possibility, the hypothetical truncated GSH-Px encoded in the +1 frame 
could potentially accumulate in infected cells and serve the virus in some regulatory or defensive 
role, e.g., to antagonize apoptotic defense mechanisms of the immune system that use oxidative 
processes to kill infected cells (52). 
 
This potential GSH-Px gene in CVB3 may also be of some significance in regard to the specific 
mutations observed by Beck et al. in the conversion of an avirulent strain into a more 
cardiovirulent strain (27), because one of the mutations consistently associated with the 
phenotypic change was in the vp3 gene. Thus, it is possible that this mutation might in some way 
modify the GSH-Px-related activity in the hypothetical GSH-Px-vp3 fusion protein described 
above, possibly thereby contributing to the greater virulence observed even in Se-adequate 
animals. 
 
A Potential Selenoprotein Gene Overlapping the HIV-1 Protease Coding Region 
 
One of the most intriguing potential new genes we predicted in HIV overlaps the protease gene 
and would have to be expressed by a -1 frameshift from protease; thus, we have tentatively 
called it the protease fs or pro fs gene (31). The hypothetical protein it encodes has significant 
similarities to a number of known DNA-binding proteins, which is consistent with its high 
content of basic amino acids (computed isoelectric point > 11). Thus, if real, it is likely to be 
either a nuclear protein or possibly an RNA binding protein. We showed that it conformed to a 
multiple sequence alignment of a known type of viral DNA-binding protein, the family of 
papillomavirus E2 proteins (31). A collaborator at Ohio State University (Robert J. Hondal in the 
lab of Ming-Daw Tsai) has created a bacterial expression vector for the cysteine homolog of this 
hypothetical HIV selenoprotein (because it is impossible to clone mammalian selenoproteins in 
bacteria directly). By mutagenesis, Cys codons were substituted for the two UGA codons in this 
protein; however, one of these aligns with a conserved Cys codon in the E2 proteins, so the 
substitution is not necessarily inconsistent with activity. Results to date indicate that this protein 
appears to have biological activity, because activation of the promoter of the expression 
construct leads to growth inhibition in the transfected bacteria (this did not occur with control 
constructs from which the viral coding sequence was omitted). This result was somewhat 
expected, because the E2-1ike palindrome that we pointed out in the HIV-1 long-terminal repeat 
as a potential target for this protein, although extremely rare in human DNA other than in a few 
cytokine-related genes (31), is found in a number of bacterial genes associated with intermediary 
metabolism, leading to a concern about the feasibility of cloning it in bacteria (i.e., if it binds to 
that palindrome, it could interfere with expression of some bacterial genes). 
 
Our interest in this potential gene has recently been stimulated by the discovery of a new family 
of RNA PKs, initially in certain bacteriophages, sharing an unusual topology involving a single 
base in the 5'-loop, spanning a 3'-stem of 6 or 7 bp (53). Du et al. showed not only that this 
remarkable structure was feasible (by NMR studies), but also that a large number of known 
frameshift and suppression sites in retroviruses had potential PKs consistent with this topology, 
which they called common pseudoknot motif 1 (CPK1). 
 
 
Fig. 5. The known HIV-1 gag-pol -1 frameshift site and pseudoknot in CPK1 topology (53), 
compared to a proposed -1 frameshift site in the HIV-1 protease coding region (31). In both 
cases, the slippery sequence comes right up to the base of the 5'-stem of the PK, and the PKs are 
similar except for several extruded bases in the helices of the protease PK structure. A potential 
CPK1 previously identified in feline leukemia virus (FeLV) (53), is shown for comparison to 
illustrate that such single-base extrusions are relatively common. 
 
One such known frameshift site where they found a potential CPK1-type PK was the gag-pol 
frameshift site in HIV-1. This may have implications for the potential frameshift in the 
hypothetical pro fs gene, because, by extending the 3'-stem of the PK structure that we originally 
proposed for the protease PK (31), a CPKl-type PK (with a single A in the 5'-loop) is obtained 
(Fig. 5). A comparison of this structure and the HIV-1 gag-pol PK in CPK1 topology also shows 
that in both cases, the heptameric frameshift sequence comes right up against the base of the 5'- 
stem of the PK (Fig. 5). Thus, this hypothetical pro fs frameshift signal is structurally almost 
identical to the known gag-pol frameshift signal. Although the pro fs heptameric shift sequence 
is not "ideal," as we pointed out previously (32), it still permits two out of three cognate base 
pairs on both tRNAs after slippage, with the mismatched base pairs potentially both being GU, 
with the appropriate tRNA isoacceptors. We are now initiating in vitro studies to attempt to 
quantitate the frameshift efficiency associated with this novel site in HIV-1. 
 
It must also be noted that the first UGA codon in this region of the -1 frame overlapping the 
HIV-1 protease gene is conserved in all known isolates and subtypes of HIV-1 currently archived 
in the Los Alamos data base; this is the UGA that aligns with the conserved Cys codon in the 
DNA recognition helix of the papillomavirus E2 proteins (31). The second in-frame UGA is 
conserved throughout HIV-1 subtypes B and D, except for a single type B isolate in which it has 
mutated to an Arg codon (perhaps significantly, in the alignment of the hypothetical protein 
sequence with papillomavirus E2 proteins, the most common residue at this point is Arg). The 
frameshift slippery sequence is conserved only in subtypes B, D, and U, but not in subtypes A 
and O. 
 
Potential structural features within the HIV protease coding region that are possibly associated 
with SeC insertion, i.e., capable of acting as SeC insertion elements (29), will be described in a 
later section. 
 
A Novel Frameshift Site and Conserved UGA Codon Overlapping the HIV-1 nef Coding Region 
 
As pointed out previously (32), the nef coding region of HIV-1 contains a highly conserved 
"ideal" -1 frameshift sequence (UUUAAAA) followed by an RNA PK, with a well-conserved 
UGA codon in the -1 reading frame. The high degree of conservation of this UGA codon raises 
the possibility that this region overlapping the nef gene may encode a selenoprotein, although 
there are several possible alternatives (discussed below). 
 
The frameshift heptamer and PK structure appear to be remarkably well conserved in all of the 
HIV-1 subtypes for which data are available. In only 5 of 76 nef sequences in the data base is 
there variation from the UUUAAAA sequence, and in all of those there is still considerable 
frameshift potential. Four of those five have mutated to UUUAAGA, which still has high slip 
potential because of the known role of Arg codons (AGA in this case) as "hungry codons," thus 
facilitating slippage at the ribosomal P-site (on UUUA). In the remaining exception, P-site 
slippage involving a single tRNA (on UUUU) is also a possibility. 
 
In addition, the potential PK structure immediately downstream of the slippery sequence is very 
well conserved in HIV-1 isolates, as shown in Fig. 6. Note that this PK topology is somewhat 
different than what we originally proposed (32); this structure is more consistent with the 
nucleotide variations in the various HIV-1 subtypes, as well as within individual subtypes. 
Again, it is interesting that the structure appears to be another example of the CPKl-type PK, 
because there is a single nucleotide in the 5'-loop spanning a 6-bp helical stem (an A in over 80% 
of all HIV-1 isolates). 
 
 
Fig. 6. An ideal heptameric -1 frameshift sequence and PK in the nef coding region of HIV-1. 
Both the PK structure and the heptamer are well conserved in HIV-1 variants (see text). The 
overlapping -1 reading frame contains several well-conserved UGA codons (see Fig. 7). 
Experiments have confirmed that this viral sequence induces a -1 frameshift, at about 5% 
efficiency in a standard assay (49). 
 
As mentioned above, we now have firm experimental evidence that these conserved structural 
features (slip site and PK) are functional, because we have been able to demonstrate significant 
levels of frameshifting in an in vitro frameshift assay (49), using a construct containing an 
oligonucleotide corresponding to this 60-base sequence from the HIV-1 nef coding region (Fig. 
6). Thus, we can say with confidence that at the least this neffs gene may encode a truncated 
isoform or variant of the nef protein, produced by the frameshift into this region followed by 
termination at the UGA codon. Alternatively, any type of opal suppression, including SeC 
insertion, would permit readthrough of the UGA and thus the attachment of an additional protein 
sequence encoded downstream in the -1 frame. 
 
A compelling argument that there must be readthrough of the UGA comes from the fact that 
there is additional conservation of sequences in the -1 frame downstream of that first UGA, 
including a second UGA that occurs in the context of the sequence CCCUGA (beginning at base 
8752 in the HIV-1 sequence, Genbank #K02013). CCCUGA is a known +1 frameshift signal in 
Escherichia coli (43). This suggests the intriguing possibility that the nef fs -1 frameshift 
discussed above could ultimately be followed by an efficient +1 frameshift returning to the 
original nef reading frame, leading to the "swapping" of the portion of the normal nef protein 
encoded in this region for an alternate module encoded in the overlapping -1 frame. Since the 
number of amino acids in both isoforms would be the same, this hypothetical variant nef protein 
would probably not be distinguishable from the normal nef protein on Western blots, and most 
antibodies would crossreact. Note that for this variant to be formed, there would have to be 
readthrough rather than termination at the first conserved UGA codon in the -1 frame (Fig. 7). 
 
 
Fig. 7. Codon usage in the HIV-1 nef gene in relation to conservation of a UGA codon and 
CCCUGA sequence in the overlapping -1 reading frame. This region is downstream of the 
frameshift site shown in Fig. 6. As indicated, the nef codons at i (Leu) and iii (Pro) could use any 
base in their third codon positions (owing to the degeneracy of the genetic code), yet U is almost 
always seen in the 76 different HIV-1 isolates, suggesting conservation of UGA codons in the -1 
frame. Similarly, the Phe codon at ii is almost always UUC rather than UUU, which suggests 
conservation of a CCC (Pro) codon in the -1 frame. The sequence CCCUGA is a known +1 
frameshift signal, which could cause a return to the nef ORF after insertion of an alternate 
protein module encoded in the -1 frame. Conservation of the CCCUGA downstream of the first 
UGA suggests that the latter must be suppressed by readthrough, i.e., the first UGA encodes an 
amino acid rather than a termination event. 
 
The rare HIV-1 subtype O (with only two isolates) is clearly unique in regard to this overlapping 
reading frame, because upstream from the first UGA in the -1 frame, it has a UAA stop codon 
not found in the other subtypes, and the UGA has mutated to GGA (Gly). 
 
Excluding the two type O isolates, the first in-frame UGA codon in the overlapping -1 reading 
frame is present in all but 2 of the remaining 74 nef sequences in the Los Alamos HIV-1 
sequence data base (one of which has mutated to an AGA [Arg] codon, and one to a UAA stop 
codon). This is remarkable in light of the fact that if only the nef gene in the zero frame is 
considered, there is no reason for the U of the UGA to be conserved, because the U is the last 
base of a leucine codon in nef, and owing to the degeneracy of the genetic code, any of the 4 
bases should be permitted in that position (Fig. 6). Because of properties inherent in the 
transcriptional infidelity of reverse transcriptase, the HIV genome also tends toward a high A 
content ("A pressure"), so in a large set of divergent HIV-1 sequences, one would expect to see a 
high frequency of A bases in the third position of leucine codons, in the absence of overlapping 
genes. 
 
As detailed in the legend to Fig. 7, the same argument applies to the well-conserved potential +1 
frameshift sequence CCCUGA located slightly downstream. This second UGA is conserved in 
all but three isolates, where it has mutated to an Arg codon, which might still permit it to 
function as part of a +1 frameshift signal via a hungry codon mechanism. 
 
The extent of conservation of these sequences is essentially identical to the degree of 
conservation of the nef ORF itself within this set of sequences, i.e., in 3 of 76 HIV-l-related 
sequences in the data base, the zero frame nef ORF is truncated because of premature termination 
at a stop codon in the middle of the frame (this includes the original HTLVIII sequence first 
reported by Gallo and coworkers (56), also called BH10). This may reflect the fact that the 
selective pressure to maintain the nef gene is only fully present in vivo, but not in cultured cells. 
Thus, we can fairly say that the sequence and structural features related to this hypothetical neffs 
gene (-1 frameshift signal, UGA and CCCUGA) are as well conserved within this set of HIV-1 
sequences as the nef ORF itself. 
 
In summary, the existence of this highly conserved UGA codon and CCCUGA sequence in the -
1 frame, downstream of an "ideal" heptameric shift and fairly large PK, is strongly suggestive of 
the presence of a novel protein module overlapping the nef gene, possibly a selenoprotein 
module. However, we cannot rule out the possibility that simple termination or perhaps some 
other type of opal suppression could be taking place at this conserved UGA codon. In fact, all 
three possibilities could occur depending on intracellular conditions, such as the relative 
abundance of tRNASec, opal suppressor tRNAs, and release factor. 
 
OTHER VIRUSES THAT MAY ENCODE SELENOPROTEINS 
 
Mouse Mammary Tumor Virus 
 
In the light of our HIV results, MMTV is a prime candidate for this analysis, because it is 
probably the only retrovirus that has been proven to be sensitive to the chemoprotective effects 
of Se. In numerous studies, Schrauzer et al. has demonstrated that the incidence of mammary 
tumors consequent to infection with MMTV is dramatically reduced by increasing dietary Se (6). 
The relevance of this animal model to human disease is considerable: aside from the obvious 
implications for AIDS and other retroviral diseases, the implications for human cancer are now 
quite inescapable in light of the recent discovery of sequences highly homologous to the MMTV 
envelope gene in 38% of human breast cancer specimens (54). 
 
A preliminary examination of MMTV for possible selenoprotein coding potential reveals several 
regions overlapping the MMTV gag gene that have appropriate frameshift signals capable of 
accessing PPCRs containing multiple in-frame UGA codons (Fig. 8). There are two PPCRs in 
the -1 frame to gag, both having potential -1 frameshift entry sites at their 5'-ends (indicated at A 
and B in Fig. 8). Site A has the potential slip sequence UAAAAGA, which is an excellent 
candidate for P-site slippage on UAAA, with AGA acting as a hungry Arg codon. This is 
followed 3 bases downstream by a small PK having >50% GC base pairs (not shown). The 
overlapping PPCR associated with site A has eight in-frame UGA codons. The second UGA-rich 
PPCR overlapping the MMTV gag gene contains four tandem UGA codons, downstream of 
potential frameshift site B (Fig. 8) with an ideal heptameric -1 frameshift sequence 
(AAAGGGA) and a PK that, like the HIV-1 gag-pol and potential HIV protease PKs (Fig. 5), 
appears to be another example of the Hoffman CPK1 type PK topology (Fig. 9). 
 
 
Fig. 8. PPCRs overlapping part of the MMTV gag gene. Numbers correspond to nucleotides in 
the genomic sequence (Genbank #D16249). A and B are possible -1 frameshift sites that could 
provide entry into the indicated PPCRs. Dashed lines are UGA codons. 
 
 
Fig. 9. A: The known HIV-1 gag-pol -1 frameshift site and PK in CPK1 topology (53), for 
comparison to B: potential frameshift site B in MMTV, with ideal heptamer and CPKl-like PK, 
located upstream from four tandem in-frame UGA codons (see Fig. 8). 
 
Schrauzer et al. (57) has noted antagonism between dietary zinc and the chemoprotective effects 
of Se vs MMTV. Thus, it may be significant that the closely spaced UGA codons in these PPCRs 
are somewhat reminiscent of the Cys residues in metallothionein, suggesting the possibility of a 
metal ion chelating role. It should also be noted that the MMTV gag gene encodes a zinc finger 
module just downstream of the region shown in Fig. 8. Thus, if expressed, these hypothetical 
selenoproteins would be formed in small amounts as alternative modules to the zinc finger 
region. Whether they might interact with zinc ions or zinc fingers, contributing to the observed 
antagonism, remains to be determined. 
 
Hepatitis B Virus (HBV) 
 
Of other viruses we have examined, HBV is notable for having been shown to have reduced 
pathogenicity in Se-supplemented human populations (1,2). Although classified as DNA viruses, 
hepadnaviruses like HBV are closely related to retroviruses in that they utilize an RNA 
intermediate and encode a reverse transcriptase enzyme. Thus, it is highly significant that a 
potential -1 frameshift sequence and large RNA PK can be found overlapping the region 
encoding the YMDD active site codons of the HBV reverse transcriptase (Fig. 10), because this 
is precisely the same location where a PK that we predicted in HIV-1 has now been supported by 
chemical and enzymatic stability studies (46). The fact that both HIV-1 and HBV have quite 
divergent slippery sequences and PK topologies suggests that what are being conserved in these 
two distant relatives are simply the elements necessary to produce a frameshift into the -1 frame, 
along with its conserved UGA codon overlapping the YMDD sequence of the polymerase. If this 
overlapping PPCR is functional, it is possible that it may be an ancient feature of reverse 
transcriptase, possibly predating the divergence of these two types of viruses. Alternatively, the 
existence of these similar structural elements in HBV and some retroviruses might reflect a 
homologous recombination event that could have taken place in more recent times. 
 
 
Fig. 10. A large potential PK and heptameric -1 frameshift sequence in HBV (Genbank 
#X51970), overlapping the active site codons of the viral reverse transcriptase. A PK predicted in 
precisely the same location in HIV-1 (31) has now been supported by enzymatic and chemical 
stability studies (46). 
 
DNA Viruses 
 
At this point in time, the most compelling evidence for a virally encoded selenoprotein is 
actually in a DNA virus: the pox virus M. contagiosum, which, as mentioned previously, was 
recently shown to encode an ORF with 80% sequence identity to the known mammalian 
selenoprotein GSH-Px (48). Although such a high level of sequence homology probably reflects 
the recent acquisition of a copy of a cellular gene, the fact that the virus has retained it shows that 
a virus can gain some advantage from encoding its own antioxidant protein. This would permit a 
virus to regulate oxidant tone within the infected cell, possibly to repress its own transcription 
(since that is typically activated by oxidative stress), and also for defensive purposes. The latter 
could be quite important in light of accumulating evidence (52) that cytotoxic T-cells can invoke 
oxidative stress in target cells (e.g., by Fas-mediated stimulation) in order to kill them by 
programmed cell death (apoptosis). A virally encoded GSH-Px or other antioxidant protein 
might be used to counter such an attack, and permit the infected cell to live longer and ultimately 
produce more viral progeny. 
 
The fact that DNA viruses can have massive genomes in comparison to most RNA viruses 
clearly presents a greater potential for incorporating specialized genes, such as antioxidant or 
selenoproteins, but at the same time can make finding them more difficult. We have observed 
several quite large UGA-rich PPCRs in certain herpesviruses (e.g., cytomegalovirus and Epstein-
Barr) with start codons and up to 11 in-frame UGA codons spanning over 400 amino acids. 
However, we have so far not been able to find any obvious analogs of known eukaryotic SECIS 
elements closely associated with these UGA-rich PPCRs. We have also noted a remarkable 
stretch of multiple tandemly repeated TGA codons near the replication origin of some 
herpesviruses, but can presently offer no insights regarding their possible significance. 
 
RNA Viruses and the Possibility of Nonspecific Selenoprotein Synthesis 
 
Because of the known role of Se in blood-clotting mechanisms and the thrombotic and even 
hemorrhagic effects of Se deficiency, we have been particularly interested in the possibility that 
hemorrhagic fever viruses might be able to incorporate SeC in some viral proteins. This is 
discussed at length in the accompanying article (55). 
 
The causative agents in viral hemorrhagic fevers are generally single-stranded RNA viruses, 
which as a class have recently been shown to have significantly higher than expected numbers of 
UGA codons in the -1 reading frame overlapping the known ORFs of many of their genes, e.g., 
up to threefold higher than expected in paramyxovirus N genes (30). Given that frameshifting in 
viruses is most commonly in the -1 direction, the -1 frame is precisely where one would expect 
to find a virally encoded selenoprotein, for which expression by the inefficient frameshifting 
process would be preferred because of the low abundance of tRNASec. It is also possible that 
some of these overlapping UGA-rich PPCRs might be vestigal remnants of ancient 
(seleno)proteins now relegated to inactive reading frames. 
 
Alternatively, even if there is no programmed synthesis of selenoproteins taking place, a low 
frequency of translational slippage into these frames would be expected to occur on a purely 
random basis, leading to encounters with in-frame UGA codons, proportional to the density of 
UGAs in the overlapping frames. Rima suggests that this might be the purpose of the high stop 
codon density: to bring about rapid termination of erroneously frameshifted protein chains (30). 
However, because stop codon recognition by termination factors is known to be slow relative to 
tRNA recognition (the basis of the "shifty stop" frameshift mechanism [39]) and because 
tRNASec has the cognate anticodon for UGA, it is possible that during the translational pause 
before the release factor is able to bind, SeC could be inserted at some small fraction of the UGA 
codons encountered during such random translational events. Even if such events were quite 
rare, they might make an impact on intracellular host SeC levels if the virus was replicating at 
extremely high rates, particularly if it had a high enough density of UGAs in the overlapping 
frames. In essence, this would be nonspecific selenoprotein synthesis, i.e., taking place without 
the involvement of RNA stem-loop SeC insertion elements. Although such aberrant SeC-
containing proteins would be difficult to detect individually owing to their low concentrations 
and structural diversity, their cumulative effect on cellular SeC pools could be significant. The 
possible implications for hemorrhagic pathology are discussed elsewhere (55). 
 
SPECIFIC SELENOPROTEIN SYNTHESIS: THE PROBLEM OF POTENTIAL VIRAL 
SECIS ELEMENTS 
 
To produce consistent and usable amounts of protein, any specific programmed selenoprotein 
synthesis by a virus would require a cotranslational mechanism identical or analogous to that 
involving eukaryotic SECIS elements or the equivalent RNA stem-loop structures in bacteria. 
Such elements are necessary in order for SeC insertion at UGA to compete successfully with 
release-factor-mediated protein chain termination. 
 
The greatest challenge to the viral selenoprotein theory at present is to demonstrate such SeC-
insertion activity at any specific viral UGA codon, which to date has not been accomplished. 
However, very little experimental effort has been expended in this direction. To our knowledge, 
only three candidate viral elements have so far been tested for ability to direct SeC insertion in a 
human 5'-deiodinase gene construct, all with negative results (Nadimpalli et al., unpublished 
data). These include a region of the HIV-1 pol gene and a region downstream of the potential 
CVB3 selenoprotein with EGF homology, both suggested previously as potential viral SECIS 
elements (32). The third was one of three potential SECIS elements that we identified in Ebola 
virus, shown as putative SECIS A in Fig. 3 of ref. (55). Of these, the one in CVB3 still merits 
further study because it was tested using a synthetic oligo that was designed with terminal 
"clamps" owing to its short length, which may have adversely affected activity by stabilizing the 
incorrect (computed rather than actual) base stem structure. It will be retested in its natural RNA 
structural context by using a larger region of CVB3 obtained by subcloning from the viral 
genome. 
 
A number of points merit consideration in regard to the possibility of specific SeC insertion in 
viral proteins. The fact that GSH-Px homologs or distinctive GSH-Px-related sequences have 
now been reported in a pox virus (48) and in Coxsackie viruses (this work) strongly suggests that 
such insertion is likely to be taking place, at the least providing incentive for further study of this 
possibility. These are also the first examples of hypothetical viral selenoproteins whose activity 
could be predicted with confidence; since there are established assays for GSH-Px activity, it 
should be easy to prove in vitro that these are functional selenoproteins, even before the exact 
location of the viral SECIS element might be identified. 
 
We must also consider the possibility that viruses might use a unique mechanism for SeC 
insertion or a variant of a known mechanism, particularly considering the significant differences 
that exist between bacterial and eukaryotic SeC insertion methods. For example, it may be 
significant that in some bacterial selenoproteins, the RNA structure downstream of the coding 
UGA can alternatively exist as a PK rather than as a simple stem-loop structure (e.g., Fig. 11A, 
in glycine reductases; Fig. 11B, in formate dehydrogenase). This raises the possibility that RNA 
PKs might be able to play a role in SeC insertion, which would also be consistent with the well-
established role of RNA PKs in retroviral suppression of other stop codons (34). Many of the 
potential coding UGAs that we have pointed out, particularly in HIV-1, are on or near PKs. Even 
the potential coding UGA in the hypothetical CVB3 GSH-Px homolog is adjacent to a possible 
RNA PK, analogous to the situation in some bacterial selenoprotein genes (Fig. 11). This 
suggests that SeC insertion in some viral genes might involve a local signal akin to that in 
bacteria, rather than the more versatile eukaryotic SECIS mechanism, which permits any in-
frame UGA to be decoded as SeC. 
 
 
Fig. 11. Potential RNA pseudoknots adjacent to SeC-encoding UGA codons in bacterial 
selenoproteins. A: In Clostridium sticklandii glycine reductase (Genbank #M60399); B: in E. 
coli formate dehydrogenase (Genbank #M13563); C: a possibly similar situation in the 
hypothetical CVB3 GSH-Px homolog. The underlined UGA is the one shown aligned with the 
catalytic SeC of GSH-Px in Fig. 2. 
 
 
Fig. 12. RNA structure predicted for a portion of the HIV-1 protease coding region, where a 
selenoprotein may be encoded in the overlapping -1 reading frame (31). The two potential 
coding in-frame UGAs (shown in braces) are located in complementary regions that form a stem 
with an embedded 5'-AUGA, forced to pair with UGAU-3' as shown in detail in the inset. This 
structure has many features characteristic of a eukaryotic SECIS element, yet rather than being in 
an untranslated region, the AUGA and UGAU involve the potential coding UGAs, a situation 
akin to a bacterial SeC insertion element. This structure is the global energy minimum predicted 
by the Zuker FOLD program (stability = -17.2 kcal/mol), as implemented in the GCG software 
package (Program Manual for the Wisconsin Package, Ver. 8, September 1994, Genetics 
Computer Group, 575 Science Drive, Madison, WI 53711). 
 
Along these lines, we have identified possible structural features in HIV-1 that may suggest how 
SeC might be inserted at the two conserved UGA codons in the hypothetical protein overlapping 
the HIV protease coding region. It seems more than coincidental that these two in-frame UGAs 
are both in the context of local sequences that are complementary to each other, and thus can pair 
to make an RNA stem structure in which the coding UGAs are forced to base pair with each 
other. As shown in Fig. 12, this gives a stem with an AUGA on the 5'-arm pairing with a UGAU 
on the 3'-arm, with a forced noncanonical G-G base pair in the center. These are precisely the 
consensus bases found in the stem region of most eukaryotic SECIS elements (29), and the 
pairing to form the G-G base pair is consistent with current models of SECIS structure and 
function (Berry and Low, personal communication). Note that this AUGAUGAU paired stem 
region is about 8-10 bp below a bulge region with runs of unpaired A bases, which is also a 
conserved feature of SECIS elements. Thus, this region of HIV has many features of a 
eukaryotic SECIS element. However, at the same time, it is more like a bacterial element, 
because it is located in the coding region, and the UGAs in the stem are the potential coding 
UGAs, whereas eukaryotic SECIS elements are always located in 3'-untranslated regions. 
 
We previously pointed out an RNA stem-loop structure in the repeat region of the HW-1 long-
terminal repeat that is very similar to the SECIS of the 5'-deiodinase gene, except that the stem is 
shorter and lacks the AUGA-UGAU sequences in the lower stem (31). Since that AUGAUGAU 
region probably interacts with the anticodon loop of tRNASec, it is possible that the upper stem-
loop with the AAA sequence may be all that is required to bind the eukaryotic SelB homolog. If 
so, SelB homolog binding to the HIV-1 stem-loop might be able to inhibit partially the 
termination factor even in the absence of an ability to bind t tRNASec, and the presence of copies 
of this structure at both ends of the HIV-1 mRNA might decrease termination efficiency at all in-
frame UGA codons in the HIV-1 genome. That could favor any type of termination suppression 
at UGA, even under conditions of Se depletion, which might be advantageous because it would 
permit various amino acids to be inserted at UGA depending on cellular conditions. 
 
Whatever its function, it would appear that this structure is of some importance to the virus, 
because the stem and the UAAAG sequence on it (which is identical to that of the 5-deiodinase 
SECIS) are absolutely conserved in all known HIV-1 isolates. Such a mechanism, particularly if 
combined with a local SECIS-like signal favoring SeC insertion (possibly a pseudoknot or a 
structure in the coding region, such as that shown in Fig. 12) would ultimately be even more 
versatile than the eukaryotic SECIS system, because it could simultaneously permit various 
amino acid translations of different UGA codons in the genome, depending on their context. 
 
Clearly, such speculations aside, there is as yet no concrete evidence of a specific SeC insertion 
mechanism in any viral genes. However, that possibility must be evaluated in the context of the 
rest of the data, both theoretical and otherwise, that we have reviewed in the previous sections. 
 
CONCLUSIONS 
 
Although there is still no definitive proof that some viruses can encode selenoproteins, we have 
reviewed a fairly extensive body of evidence that tends to favor that possibility. It is probably 
only a matter of time before functional GSH-Px-like activity will be demonstrated in several 
viruses where GSH-Px-related sequences have now been identified (48). In addition, certain 
previously predicted genomic features in HIV-1 that are associated with highly conserved UGA 
codons in overlapping reading frames have now been experimentally confirmed, including a 
novel RNA PK (46) and a functional -1 frameshift site in HIV-1 (49). 
 
Despite these encouraging developments, an immense amount of work remains to be done before 
we will be able to assess definitively the extent to which viruses may directly or indirectly utilize 
or impact on selenobiological processes inside infected cells, if indeed they do at all. However, 
there is no doubt that Se has an effect on viruses, as these symposium proceedings attest. The 
question is; What are the mechanisms underlying that effect? Hopefully, the data presented here 
will inspire researchers from related fields to consider ways in which this fascinating question 
might be best resolved. 
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